Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VTYX
Upturn stock ratingUpturn stock rating

Ventyx Biosciences Inc (VTYX)

Upturn stock ratingUpturn stock rating
$3
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VTYX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.5

1 Year Target Price $11.5

Analysts Price Target For last 52 week
$11.5 Target price
52w Low $0.78
Current$3
52w High $3.39

Analysis of Past Performance

Type Stock
Historic Profit -67.36%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 213.93M USD
Price to earnings Ratio -
1Y Target Price 11.5
Price to earnings Ratio -
1Y Target Price 11.5
Volume (30-day avg) 9
Beta 0.97
52 Weeks Range 0.78 - 3.39
Updated Date 08/15/2025
52 Weeks Range 0.78 - 3.39
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.66

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.46
Actual -0.38

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -30.23%
Return on Equity (TTM) -48.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 15261554
Price to Sales(TTM) -
Enterprise Value 15261554
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -22.93
Shares Outstanding 71308496
Shares Floating 55662716
Shares Outstanding 71308496
Shares Floating 55662716
Percent Insiders 4.11
Percent Institutions 67.33

ai summary icon Upturn AI SWOT

Ventyx Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines for autoimmune and inflammatory diseases. It was founded in 2020. The company's strategy involves acquiring or in-licensing promising drug candidates and advancing them through clinical development.

business area logo Core Business Areas

  • Drug Development: Focuses on the development of oral, small molecule therapies targeting validated biological pathways for autoimmune and inflammatory diseases.

leadership logo Leadership and Structure

The company is led by a management team with experience in drug development and commercialization. Specific leadership details would require real-time search as personnel changes are common. The structure is typical for a biotech company, with research and development, clinical operations, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • Vtx-958: A selective allosteric TYK2 inhibitor being developed for psoriasis, psoriatic arthritis, and Crohn's disease. Clinical trials are ongoing. Competitors include BMS's Sotyktu and other TYK2 inhibitors in development. Market share is currently zero due to being in clinical trials, but represents an entry into a large and growing market.
  • Vtx-801: An NLRP3 inhibitor being developed for various inflammatory conditions. Clinical trials are ongoing. Competitors include other companies developing NLRP3 inhibitors, such as Olatec Therapeutics. Market share is currently zero due to being in clinical trials, but represents an entry into a large and growing market.
  • Vtx-3232: A peripheral S1P1 receptor modulator in development for autoimmune diseases. Clinical trials are ongoing. Competitors include other S1P modulators like ozanimod (Zeposia) from BMS. Market share is currently zero due to being in clinical trials, but represents an entry into a large and growing market.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry for autoimmune and inflammatory diseases is large and competitive, driven by high unmet medical needs and increasing prevalence of these conditions.

Positioning

Ventyx aims to differentiate itself by developing oral, small molecule therapies with improved efficacy and safety profiles compared to existing treatments. Their competitive advantage lies in their targeted approach to validated biological pathways.

Total Addressable Market (TAM)

The TAM for autoimmune and inflammatory disease treatments is estimated to be over $100 billion globally. Ventyx is positioned to capture a portion of this market with its pipeline of drug candidates. The precise addressable market for each product is dependent on the specific indications they are targeting.

Upturn SWOT Analysis

Strengths

  • Promising drug pipeline targeting validated pathways
  • Experienced management team
  • Oral, small molecule approach offers convenience
  • Strong intellectual property portfolio

Weaknesses

  • Clinical trial risk
  • High cash burn rate
  • Dependence on successful clinical trial outcomes
  • Limited commercial infrastructure

Opportunities

  • Successful clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Potential for breakthrough therapies

Threats

  • Competition from established players
  • Regulatory hurdles
  • Patent challenges
  • Unfavorable clinical trial data

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • PFE
  • ABBV

Competitive Landscape

Ventyx faces competition from established pharmaceutical companies with marketed products and other biotech companies developing similar therapies. Ventyx's success depends on demonstrating superior efficacy and safety in clinical trials.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by expansion of the drug pipeline and advancement through clinical trials.

Future Projections: Future growth is contingent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary depending on perceived probabilities of success.

Recent Initiatives: Recent initiatives include progressing lead drug candidates through clinical trials, initiating new clinical studies, and potential strategic collaborations.

Summary

Ventyx Biosciences is a clinical-stage biopharmaceutical company with a focus on autoimmune and inflammatory diseases. The company's strength lies in its promising drug pipeline and experienced management team. However, it faces risks associated with clinical trial outcomes and competition from established players. Successful clinical trials and potential partnerships will be crucial for its future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data and is subject to change. Invest at your own risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ventyx Biosciences Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2021-10-21
Founder, CEO, President & Director Dr. Raju S. Mohan Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 81
Full time employees 81

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.